SAN FRANCISCO -- First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant metastatic colorectal cancer (mCRC), according to the BREAKWATER ...
The FDA approved encorafenib (Braftovi) plus binimetinib (Mektovi) for BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC) as determined by an FDA-approved test, the agency announced on ...
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix Part 2 of the ...
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...
Circulating tumor DNA (ctDNA) is emerging as a blood-based biomarker for many solid tumor types, including melanoma. A new study that assessed ctDNA in the blood of patients with BRAF wild-type (BRAF ...
Phase III trial results supported recent FDA approval for patients with BRAF V600E mutations Data from this multi-institutional collaboration across 28 countries supported the accelerated approval of ...
Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial Fifty-eight patient tumors (56%) harbored ...
The US Food and Drug Administration (FDA) has approved encorafenib (Braftovi, Pfizer) with binimetinib (Mektovi, Array BioPharma) for adults with metastatic non–small cell lung cancer (NSCLC) that ...
BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results